SEC Company Response from GSK (GSK) — Jul 7, 2008
GSK plc
Date: July 7, 2008 · CIK: 0001131399 · Accession: 0000903423-08-000555
AI Filing Summary & Sentiment
Referenced dates: June 26, 2008
Letter
Division of Corporation Finance Securities and Exchange Commission Washington, D.C. 20549 United States Re: Comment Letter—GlaxoSmithKline plc (“GSK”) Annual Report on Form 20-F for 2007
Dear Mr. Rosenberg:
We appreciate the opportunity to speak with your colleague Gus Rodriguez on July 3 in connection with the comment letter dated June 26, 2008 relating to GSK’s Annual Report on Form 20-F for 2007. As requested, this is a brief note to indicate that GSK intends to respond to the comments by July 31, 2008.
Although the comments are not extensive, the preparation of appropriate responses will require the involvement of a number of GSK executives and financial and legal department staff, as well as members of the GSK audit team from PricewaterhouseCoopers and outside counsel. Arranging for this involvement in order to meet the requested deadline would be difficult, particularly given the fact that GSK is in the midst of preparing its first half results.
You can reach either me, or my colleague Gerald Neugebauer, at my number above. Please do not hesitate to contact us if you have any questions or if we can be of further assistance at this time.
Yours sincerely,
/s/ Sebastian R. Sperber
Sebastian R. Sperber
cc: Mr. Gus Rodriguez, Securities and Exchange Commission
Ms. Mary Mast, Securities and Exchange Commission
Mr. Christopher Buckley, GlaxoSmithKline plc
Mr. Tom Quinn, PricewaterhouseCoopers
Mr. Andy Kemp, PricewaterhouseCoopers
Mr. Gerald Neugebauer, Cleary Gottlieb Steen & Hamilton LLP
Show Raw Text
CORRESP
1
filename1.htm
Writer's Direct Dial: +44 (0) 207 614-2237
E-Mail: ssperber@cgsh.com
July 7, 2008
BY EDGAR
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
Division of Corporation Finance
Securities and Exchange Commission
450 Fifth Street, N.W., Stop 4-5
Washington, D.C. 20549
United States
Re:
Comment Letter—GlaxoSmithKline plc (“GSK”) Annual Report on Form 20-F for 2007
Dear Mr. Rosenberg:
We appreciate the opportunity to speak with your colleague Gus Rodriguez on July 3 in connection with the comment letter dated June 26, 2008 relating to GSK’s Annual Report on Form 20-F for 2007. As requested, this is a brief note to indicate that GSK intends to respond to the comments by July 31, 2008.
Although the comments are not extensive, the preparation of appropriate responses will require the involvement of a number of GSK executives and financial and legal department staff, as well as members of the GSK audit team from PricewaterhouseCoopers and outside counsel. Arranging for this involvement in order to meet the requested deadline would be difficult, particularly given the fact that GSK is in the midst of preparing its first half results.
You can reach either me, or my colleague Gerald Neugebauer, at my number above. Please do not hesitate to contact us if you have any questions or if we can be of further assistance at this time.
Yours sincerely,
/s/ Sebastian R. Sperber
Sebastian R. Sperber
cc:
Mr. Gus Rodriguez, Securities and Exchange Commission
Ms. Mary Mast, Securities and Exchange Commission
Mr. Christopher Buckley, GlaxoSmithKline plc
Mr. Tom Quinn, PricewaterhouseCoopers
Mr. Andy Kemp, PricewaterhouseCoopers
Mr. Gerald Neugebauer, Cleary Gottlieb Steen & Hamilton LLP